Poc bnp istat1/30/2024 Then, the nanoparticles capture analyte molecules from the sample fluid. The redispersion process of the antibody-coated nanoparticles occurs in just a few seconds from a thin film of reagents when the sample enters in contact with it. Dried-in magnetic nanoparticles are redispersed and mixed into the sample fluid that enters the cartridge.In the scheme above, we can see the following steps: The Magnotech® Technology is responsible for the device's short detection time (only 8 minutes!) and high sensitivity, which is probably why Siemens Healthineers acquired Minicare in 2019, later launching the platform under the name: Atellica® VTLi Patient-side Immunoassay Analyzer. Conceived in Netherlands by scientists working at Philips (see 2007 patent below) and later developed in Philip's spin off, Minicare, the technology is based on an optomagnetic biosensor principle ( Lab Chip, 2009, 9, 3504–3510). Siemens Healthineers' device is a different thing. Generally, commercially available immunoassay analyzers and tests are either based on lateral flow assays (like pregnancy tests or rapid COVID tests), chemiluminescence (like Theranos devices - sorry for giving this example), fluorescence (like Fujifilm's veterinary POCT analyzer) or electrochemistry (like Abbott's i-Stat, that also detects cTnI, plus BNP - both cardiac markers). Apart from the fact that it is a point-of-care-test (POCT) in the form of a handheld device that works with fingerstick blood samples - the first of its kind for hs-cTnI -, the most interesting feature of this test is the bioassay design together with an unusual detection technology. In April this year, the Germany-based MedTech company Siemens Healthineers received the CE mark for a high-sensitivity cardiac troponin I (hs-cTnI) test.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |